T
he terms myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) have been used to describe a debilitating multisystemic condition characterized by chronic, disabling fatigue and various other symptoms. The term CFS was introduced in the 1980s after research failed to identify a clear viral association with what was previously labeled chronic Epstein-Barr virus syndrome (1) (2) (3) (4) . Other terms, such as postviral fatigue syndrome and chronic fatigue immune dysfunction syndrome, were also used in attempts to associate the syndrome with possible underlying causes (1, 2, 5, 6) . Although the most recent international consensus report advocates moving away from the term CFS in favor of the term ME to better reflect an underlying disease process involving widespread inflammation and neuropathology (7, 8) , experts do not agree about these mechanisms and the cause of CFS remains unclear.
A recent Institute of Medicine (IOM) report proposes a name, systemic exertion intolerance disease (SEID) , that describes the central elements of the disease. The report focuses on the adverse effect that physical, cognitive, or emotional exertion can have on patients with this condition and acknowledges that this is a complex and severe disorder for which specific causes are not yet proven (9) .
The diagnosis of ME/CFS is based on clinical criteria that attempt to distinguish it from other conditions that also present with fatigue. Eight published case definitions have been used since the first one established by the Centers for Disease Control and Prevention (CDC) in 1988 (2) , and the IOM proposed a ninth in February 2015 (9) . All include persistent fatigue not attributable to a known underlying medical condition, as well as additional clinical signs and symptoms that do not all need to be present to establish the diagnosis (10) . However, there has been no consensus about which, if any, of these clinical criteria should be considered the reference standard. The variations in case definitions imply that they may describe different conditions and lead to different diagnoses, complicating ME/CFS research and clinical care. For example, depending on the case definition, prevalence rates of ME/ CFS in the United States range from 0.3% to 2.5% (1, 11, 12) .
This systematic review is part of a larger report to inform a research agenda for the National Institutes of Health (NIH) 2014 Pathways to Prevention Workshop, an evidence-based methodology workshop (13) . The purpose of this systematic review was to evaluate and compare studies of methods to diagnose ME/CFS, identify limitations of current studies, and determine needs for future research.
METHODS
Key questions guiding this review were developed in collaboration with the NIH ME/CFS Working Group following a standard protocol, including input from key informants and a technical expert panel, registration in the PROSPERO database for systematic reviews (14) , and posting on an Agency for Healthcare Research and Quality (AHRQ) public Web site. Key questions concerned describing clinical methods for diagnosing ME/ CFS and evaluating their concordance and accuracy, describing variations in diagnostic methods by patient subgroups, and identifying consequences of diagnosis for patients. This article focuses on the published case definitions and on the concordance and accuracy of methods for diagnosis of ME/CFS. A technical report details the methods and includes an analytic framework, search strategies, and additional evidence tables (13) .
Data Sources and Searches
A research librarian searched electronic databases to identify relevant articles published between January 1988 (year of the first case definition) and September 2014: MEDLINE (Ovid), PsycINFO, the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and the National Health Sciences Economic Evaluation. Searches were supplemented by references identified from additional sources, including reference lists and experts.
Study Selection
English-language studies of adults with ME/CFS as defined by any of the established case definitions, and those for whom ME/CFS was a diagnostic consideration, were eligible for inclusion. For this review, we use the combined term "ME/CFS" when referring to the condition in general, and we use the individual terms to represent study populations fulfilling specific sets of clinical criteria defined as ME or CFS. Studies of diagnostic tests or case definitions were included if they were conducted in clinical settings or settings applicable to clinical practice settings; we excluded studies of inpatients or institutionalized individuals. We also excluded studies of disease cause and studies that reported the diagnosis of specific symptoms of ME/CFS (for example, postexertional malaise).
We included studies that 1) compared case definitions (for example, Fukuda/CDC, Canadian, International) and provided measures of agreement or 2) tested the ability of the method to identify patients with ME/CFS by using 1 of the case definitions as a reference standard and reported at least 1 of the specified outcomes. Because there is no single accepted definition for ME/CFS and therefore no "gold standard," any of the case definitions published since 1988 were accepted as reference standards. Included outcomes of diagnostic accuracy were sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, c-statistic, receiver-operating characteristic curve and area under the receiver-operating characteristic curve, net reclassification index, and concordance. Studies of any design were included if they described potential harms from diagnosis, such as psychological harms, labeling, risk from diagnostic tests, and misdiagnosis. These studies are included in the full report (13) .
Two investigators independently evaluated each study to determine inclusion eligibility. Disagreement was resolved by consensus, with a third investigator making the final decision as needed.
Data Extraction and Quality Assessment
An investigator abstracted details of the patient population, study design, setting, inclusion and exclusion criteria, population characteristics, sample size, case definition for diagnosis, and results. A second investigator reviewed extracted data for accuracy and completeness. Investigators rated the quality (risk of bias) of the individual studies on the basis of criteria adapted from the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Medical Test Reviews (15) . A second investigator reviewed ratings, and disagreements were resolved by consensus with a third investigator as needed. Quality and strength of evidence ratings were assessed for all studies of diagnostic test accuracy (comparison of a diagnostic test to a reference standard) but could not be assessed for other studies with descriptive, cross-sectional, and case series designs.
Data Synthesis and Analysis
Studies of diagnostic tests could not be combined in a quantitative meta-analysis because of heterogeneity of patient populations, study designs, reported outcomes, and reference standards. Therefore, data were synthesized qualitatively with attention to such factors as patient characteristics and risk of bias.
Role of the Funding Source
The AHRQ funded the review, and a working group convened by the NIH helped develop the review's scope and key questions. Neither had a role in study selection, quality assessment, or synthesis. The investigators are solely responsible for the content.
RESULTS
Among the 6175 abstracts identified by searches and additional papers identified through other sources, 44 studies met inclusion criteria (Appendix Figure, available at www.annals.org). These included 8 studies describing case definitions (Table) (2, 5-7, 16 -19) , 22 evaluating diagnostic tests (Appendix Tables 1 and 2 , available at www.annals.org) (1, 10, 20 -39) , and 14 describing consequences of diagnosis (Appendix Table 3 , available at www.annals.org) (11, 40 -52) . The new IOM case definition was also included for completeness (bringing the total to 9 available case definitions), even though it was published after the literature search dates.
Methods for Diagnosing ME/CFS
Nine case definitions using clinical criteria have been developed to identify patients with ME/CFS and help clinicians distinguish ME/CFS from other conditions that present with fatigue (Table) (2, 5-7, 9, 16 -19) . Although most case definitions require that other conditions be excluded before ME/CFS is diagnosed, no studies compared strategies for ruling out alternative diagnoses or specifically defined which conditions should be ruled out. The IOM case definition, published in February 2015, incorporates required elements of fatigue, postexertional malaise, and sleep disturbance, along with cognitive impairment or orthostatic hypotension (9) . The Oxford case definition incorporates the fewest symptoms (new onset of fatigue with impairment of physical and mental function), suggesting that it includes patients who would not meet other criteria for ME/CFS (19) . Concordance of Methods for Diagnosing ME/CFS Seven studies compared symptoms of patients with ME/CFS diagnosed by using different case definitions and found that symptoms varied depending on the clinical criteria used (Appendix Table 1 ) (1, 10, 20 -24) . In general, populations defined by ME or ME/CFS criteria had more severe symptoms or more functional impairment than those defined by CFS criteria alone (1, 10, 20 -24) .
Three studies enrolling a total of 6087 patients compared symptoms of patients with CFS identified by the 1994 CDC criteria with symptoms of patients without CFS (healthy controls; other fatigued patients; and patients with psychiatric, rheumatologic, and other chronic diseases) (25) (26) (27) . In general, patients without CFS were less impaired than those with CFS, although results varied. In 1 study, patients with CFS and multiple sclerosis had similar scores on the 36-item Short-Form Survey (SF-36) on physical function, vitality, and social function scales (27).
Accuracy of Measures for Diagnosing ME/CFS
Nine studies evaluated methods to discriminate ME/CFS from other conditions by using 1 of the published case definitions as a reference standard (Appendix Tables 2 and 4, available at www.annals.org) (29 -37). One study met criteria for good quality (30), 7 for fair quality (31-37), and 1 for poor quality (29). Several studies used the same or very similar study populations to report different outcomes, most commonly recruiting from CFS self-help groups (34 -36) or community samples (32, 33) . Major limitations of studies included small size (<50 participants) (29, 34 -36) , recruitment from specialty clinics only (30), lack of blinding to the reference standard result (29 -36) , and comparing cases with primarily healthy or nonfatigued controls (29, 31, (33) (34) (35) (36) .
By using computerized modeling to identify key symptoms, 3 studies found that symptom-based instruments had high sensitivity and specificity for identifying patients who meet 1 of the ME/CFS case definitions (Appendix Table 2 ) compared with healthy controls (30, 31, 37) .
Another study randomly assigned a broad spectrum of 198 participants with fatigue (including patients with systemic lupus erythematosus, fibromyalgia, and CFS defined by Oxford criteria) to derivation or validation cohorts (30). Participants completed symptom questionnaires, and the symptoms with the highest sensitivity and specificity for CFS were selected to develop and evaluate computer-generated classification criteria to distinguish patients with CFS from the other patients.
Four methods of classification were tested in the derivation cohort, and for each algorithm, the sensitivity, specificity, and accuracy were determined in the validation cohort. A strategy that included 24 symptoms, the artificial neural network, had good discriminative ability (sensitivity, 0.95; specificity, 0.85; accuracy, 0.90) (30) . This study met criteria for good quality because it included a broad spectrum of patients with conditions considered to be competing diagnoses for ME/CFS and included a validation cohort.
An evaluation of responses to the DePaul Symptom Questionnaire from 515 patients with CFS and 176 controls used K-means clustering to distinguish patients with fewer symptoms from those with more symptoms, who presumably had CFS (37). After testing of 4 methods of clustering, the unsupervised thresholding model was used to assign a diagnostic label to each participant, and the diagnosis assigned by each of 3 different clinical criteria (1994 CDC [CFS] , Canadian [ME/CFS], and 2011 International [ME]) was compared with the assigned diagnostic label. Then, the individual symptoms were ranked by predictive value and compared with the 3 case definitions and the use of all 54 DePaul Symptom Questionnaire symptoms.
Results indicated that model accuracy obtained by using the top 11 ranked symptoms was better than that obtained with all 54 DePaul Symptom Questionnaire symptoms or the 1994 CDC (CFS), Canadian (ME/CFS), and 2011 International (ME) criteria (90.2%, 82.3%, 83.8%, 84.1%, and 78.7%, respectively). The topranked symptoms corresponded to fatigue, exertional malaise, sleep disturbance, cognitive impairment, and myalgias. This study met criteria for fair quality because it lacked a validation group, but it included a relatively large, broad spectrum of participants.
In another study of 368 patients and 452 controls, the Schedule of Fatigue and Anergia for CFS Scale was developed by using a composite set of criteria as a reference standard and specific symptoms from 4 symptom checklists (31). Latent class analysis was used to select 10 symptoms having the highest correlation to CFS-like fatigue; then, a composite score was tested to determine sensitivity and specificity. The 10 symptoms included fatigue, exertional malaise, myalgias, cognitive difficulties (including poor concentration, poor memory, speech difficulties), poor sleep, and headaches. A total score of 3 to 4 out of 4 had a sensitivity of 81% for the 3-class solution and a specificity of 100%. This study met criteria for fair quality because patients were recruited from specialty clinics rather than from a broader population and because it lacked a validation cohort.
Variation in Diagnostic Testing According to Subgroups
Three studies evaluated diagnostic tests in subgroups of patients with ME/CFS (28, 38, 39) . Compared with patients younger than 25 years, patients older than 50 were more impaired, had lower self-efficacy, and had worse scores on the Fatigue Impact Scale, Chalder Fatigue Scale, Hospital Anxiety and Depression ScaleDepression subscale, and SF-36 (28). Likewise, older patients had lower resting heart rates, higher left ventricular ejection time, and lower baroreflex sensitivity (ability to maintain blood pressure) than younger patients.
Two studies of the same population evaluated the ability of self-reported function scales to predict recovery from cardiopulmonary exercise testing in patients with CFS defined by 1994 CDC (CFS) criteria and nondisabled sedentary controls (38, 39). The SF-36 subscales of physical function, role-physical, bodily pain, general health, vitality, and social functioning identified patients with failure to recover at 1 day; the subscales role-emotional, vitality, and bodily pain identified those with failure to recover at 1 week (38). Having 3 or more symptoms of postexertional malaise optimally distinguished between patients with CFS and controls (39).
DISCUSSION
Of the 8 previously published sets of clinical criteria for ME and/or CFS, case definitions for ME and ME/CFS identify patients with more impairment, lower functioning, and more severe symptoms than the CFS-alone case definitions. The new IOM case definition incorporates principal elements of previous definitions, and the association of these elements to ME/CFS is supported by modeling studies (31, 37). None of the case definitions or other diagnostic methods has been adequately tested to determine how well they differentiate patients with ME/CFS from patients with other conditions. Although some symptom-based instruments discriminate patients with ME/CFS from healthy controls, their utility in differentiating patients with diagnostic uncertainty remains inconclusive because they have not been widely tested in broad spectrums of patients. The few studies that evaluated how diagnostic tests vary by patient subgroups were inconclusive.
The clinical applicability of current research on diagnostic methods for ME/CFS is limited in several ways. All case definitions require the exclusion of competing diagnoses before assigning a ME/CFS diagnosis, yet no studies evaluated strategies for the evaluation and assignment of alternative diagnoses. In addition, most studies were designed as descriptive studies and enrolled healthy or nonfatigued participants as controls. Studies evaluated whether tests distinguished ME/CFS from these types of controls, but not the essential clinical question of whether the test could distinguish ME/ CFS from other fatiguing illnesses. Only 1 study included participants with overlapping symptoms and tested a strategy for diagnosis in both a derivation and a validation cohort; and only 2 studies evaluated a diagnostic test by using control groups of fatigued or other chronically ill patients (30). In addition, studies used varying case definitions as the reference standard precluding comparisons across studies. Finally, many studies recruited participants from specialty clinics, potentially reflecting more severe disease, or sitedependent or local practices, limiting generalizability to other patients with ME/CFS. Consistent with a prior systematic review (53), no studies identified specific patients with identifiable causes.
Future research should be based on a standard case definition, or a set of reference standards, to allow comparison of results across studies. The IOM has provided a consensus case definition that could serve this purpose. Consensus groups and researchers should consider retiring the Oxford case definition because it differs from the other case definitions and is the least restrictive, probably including individuals with other overlapping conditions. The new IOM case definition and algorithm provide a starting place for future studies of diagnostic testing.
Future studies evaluating the capability of diagnostic methods for ME/CFS should include a broad range of patients with conditions that require clinical distinction from ME/CFS, such as fibromyalgia and depression. Moreover, studies should report how well a particular method distinguishes ME/CFS from other conditions by using standard performance measures, such as concordance, sensitivity, and specificity. Studies should report findings according to important features of ME/CFS, such as postexertional malaise, neurocognitive status, and autonomic function, to identify subgroups that may respond differently to specific treatments. Collaborative groups could consider establishing an international ME/CFS registry that would track the natural history of patients to determine which set of clinical criteria best identifies patients for whom no alternative diagnosis will be found with subsequent testing, and for whom the diagnosis of ME/CFS will continue to be appropriate over time. Given the devastating effect of this condition on patients and families, researchers should involve patients and advocates in trial planning and development so that future research is relevant and meaningful to those affected by ME/ CFS.
In conclusion, 9 sets of clinical criteria are used to define ME/CFS, yet none of the current diagnostic methods have been adequately tested to identify patients with ME/CFS when diagnostic uncertainty exists. More definitive studies in broader populations are needed to address these research gaps. † Identified from such sources as reference lists, hand searches, and suggestions by experts. ‡ Studies that provided data and contributed to the body of evidence were considered "included." § Studies included for the treatment key questions are reported elsewhere (13) . || The Institute of Medicine case definition (9) is an additional case definition, which was released subsequent to the search. (Fukuda, 1994) ; Oxford (Sharpe, 1991) ACTH, plasma cortisol, salivary cortisol, differential blood count, IL-6 and TNF-alpha (baseline, and 10, 60 minutes after the TSST) German translation of the Fatigue Scale (Chalder 1993), SIP-8, SCL-90R, HADS All subjects underwent the TSST: after basal blood and saliva samples were taken they were told to prepare for a fake job interview, then given a mental arithmetic task in front of an audience and told they would be videotaped for further analysis of their behavior. The HADS, SCL-90R and SIP-8 scores were all significantly higher in the CFS group AUC for IL-6 and TNF-alpha vs. Chalder fatigue scale total score, mental fatigue and physical fatigue scores NS. CFS. ME/CFS as identified by any of 3 different case definitions: CDC (Fukuda, 1994) , Canadian, 2003 and ME-ICC DePaul Symptom Questionnaire; computerized thresholding using a k-means clustering approach.
Sensitivity, specificity, accuracy for case definition Unsupervised thresholding (UT): CDC (Fukuda, 1994): 83.1, 85.8, 83.8; Canadian (Carruthers, 2003) : 82.9, 87.5, 84.1; ME-ICC (Carruthers, 2011): 74.4, 91.5, 78.7. Supervised thresholding: CDC (Fukuda, 1994): 80.8, 86.4, 82.2; Canadian (Carruthers, 2003): 85.8, 87.5, 86.3 ; ME-ICC (Carruthers, 2011): 89.9, 81.3, 87.7. Two-two static threshold: CDC (Fukuda, 1994): 80.8, 85.8, 82.1; Canadian (Carruthers, 2003): 77.9, 89.8, 80.9 ; ME-ICC (Carruthers, 2011) 67.4, 91.5, 73.5 (sensitivity and accuracy for Fukuda and ME-ICC p = 0.01 vs. UT). One-one static threshold: CDC (Fukuda, 1994): 98.1, 42.0, 83.8 (p = 0.01 vs. UT for sensitivity and specificity); Canadian (Carruthers, 2003) : 97.3, 50.0, 85.2 (p = 0.01 vs. UT for sensitivity and specificity); ME-ICC (Carruthers, 2011) 93.4, 52.8, 83 .1 (p = 0.01 vs. UT for sensitivity and specificity). ACTH = adrenocorticotropic hormone; AUC = area under the curve; BMC = BioMed Central; CDC = Centers for Disease Control and Prevention; CFS = chronic fatigue syndrome; FMS = fibromyalgia syndrome; HADS = Hospital Anxiety and Depression Scale; IL = interleukin; LCA = latent class analysis; ME = myalgic encephalomyelitis; ME-ICC = myalgic encephalomyelitisinternational consensus criteria; MFI-20 = Multidimensional fatigue inventory; NS = not significant; PBMC = peripheral blood derived mononuclear cell; QROC = quality receiver operating characteristic; Rnase L = latent Ribonuclease; SCL-90R = symptom checklist 90-revised; SF-36 = 36-item Short Form Survey; SIP-8 = Sickness Impact Profile 8-item; SLE = systemic lupus erythematosus; SOFA = schedule of fatigue and anergia; TNF = tumor necrosis factor; TSST = Trier social stress test; UT = unsupervised threshold. CDC (Holmes, 1988) criteria vs. CDC (Fukuda, 1994) 27.3; p < 0.01 for Fukuda vs. psychiatric group All others symptoms p = NS Mean SF-36 sub-scales scores (0-100 scale, higher scores indicate better health) Bodily pain: 33.3 vs. 44.5 vs. 53.7; p < 0.05 General health: 34.9 vs. 55.5 vs. 49.9; p < 0.05 Physical health composite: 30.9 vs. 37.0 vs. 39.9; p < 0.05 for Fukuda vs. psychiatric group All other subscales and composite scales p = NS Mean degree of impairment (0-100 scale, lower scores indicate better health) 64. 1 vs. 46.5 vs. 65.6; p < 0.05 
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for Fukuda vs. psychiatric group
Continued on following page N = 114 meeting CDC (Fukuda, 1994) criteria CDC (Fukuda, 1994) , Canadian (Carruthers, 2003) , and Revised Ramsay, 1988 Measures: CFS questionnaire (validated by Jason 1997 to assess symptoms, with modified scoring system ranging from 0-100 with higher scores indicating more impairment; DSM-IV SCID interview, medical, and neurological history and exam, other explanation for CFS-like symptoms; CFS Questionnaire (Komaroff 1996) to rule out other disorders; MOS-SF; Cognitive Trailmaking Test Parts A and B Heart rate lying down, 2 minutes after standing, and 10 minutes after standing Methods: Used symptom counts, chi-square and MANOVA to assess differences between group
Of 114 people meeting Fukuda CFS criteria, 56 did not meet the ME/CFS criteria and 97 did not meet the ME criteria (56 were classified as ME/CFS and 27 as ME). 1 person was unable to be categorized. ME/CFS vs. CFS not ME/CFS Demographics differences Disability: 32% (18/ : 14.8 (12.0) vs. 20.9 (16.6); p = 0.02 Social functioning: 34.0 (22.7) vs. 46.6 (24.2) ; p = 0.01 Symptom complaints more common among ME/CFS vs. CFS not ME/CFS Fatigue: p = 0.00; PEM: p = 0.00; unrefreshing sleep: p = 0.00; need to nap each day: p = 0.05; difficulty falling asleep: p = 0.01; all pain parameters (muscle pain, pain in multiple joints, headaches, chest pain, abdomen pain, eye pain): all p < 0.02; all neurological parameters (impaired memory and concentration, abnormal sensitivity to light, slowness of thought, confusion/disorientation, difficulty finding the right work, difficulty comprehending information, need to have focus on one thing at a time): p = 0.00; all autonomic parameters (racing heart, shortness of breast, dizziness, feel unsteady on feet): p < 0.01; and tender/sore lymph nodes: all p = 0.00 Symptom complaints more common among ME vs. CFS not ME/CFS Headaches: p = 0.05; chest pain: p = 0.04; abdomen pain: p = 0.00; eye pain: p = 0.00; difficulty finding the right word: p = 0.05; need to have focus on one thing at a time: p = 0.02; all autonomic parameters (racing heart, shortness of breast, dizziness, feel unsteady on feet): all p < 0.02; tender/sore lymph nodes: p = 0.02; and hot/cold spells: p = 0.05 ME/CFS vs. CFS not ME/CFS; ME vs. CFS not ME Mean (SD) heart rate (bpm) Lying down: 80.7 (14.8) vs. 74.5 (11.1); p = 0.02; 84.4 (16.4) vs. 75.4 (11.4) ; p = 0.00 Standing 2 minutes: 94. 2 (17.1) vs. 85.7 (14.6); p = 0.00; 96.9 (18.9) vs. 87.7 (14.9) ; p = 0.00 Standing 10 minutes: 94.6 (14.5) vs. 86.2 (13.6) ; p = 0.00; 97. 8 (14.4) vs. 88.1 (13.9) ; p = 0.00 Mean (SD) Trailmaking test scores A-time: 32.9 (13.6) vs. 26.8 (9.9) 
Descriptive observational study of questionnaire data N = 68 patients met Oxford criteria (Sharpe, 1991) for CFS completed a questionnaire asking about psychiatric diagnoses or labels given during their illness and then underwent interview to assess for those psychiatric disorders with the DSM III-R.
Reported psychiatric diagnosis 46% (31/68) given psychiatric diagnosis (usually depression) 68% (21/31) given depression diagnosis were misdiagnosed 35% (13/37) not given psychiatric diagnosis met DSM III-R criteria for treatable psychiatric disorder, present for ≥6 months Dickson et al, 2007 (44) Qualitative study N = 14 people with self-reported CFS were interviewed about living with CFS.
Reported difficulties about living with CFS 71% (10/14) experienced delay in getting CFS diagnosis 57% (8/14) were prescribed antidepressants for depression diagnosis instead of CFS diagnosis Descriptive results Participants reported that they perceived many medical practitioners to hold stereotypical views of patients with CFS, namely that disease was either psychological or indicative of an affective disorder. Problems with friends and partners centered on the fact that the patient is not visibly ill, and that the symptoms are inconsistent or variable. Green et al, 1999 (45) Observation al descriptive study of survey data N = 45 of 67 (67%) initially recruited patients with CFS reported perceptions of stigma.
Reported perceptions of stigma 95% reported feeling estranged 70% thought others attribute their symptoms to psychological or personality 40% felt need to be secretive about their symptoms in some circumstances Guise et al, 2010 (46) Qualitative study of interview data N = 38 members of an internet-based ME/CFS support group were asked to comment on how they felt about the way medical people treated them.
Descriptive results
Patients with CFS reported that health professionals lack clinical expertise and empathy; and that they encountered professionals who lacked expectation of treatability, described themselves as fortunate in terms of experiences with medical professionals, and described themselves as able to cope and actively seeking out information and treatment. likely to think that the patient was correctly diagnosed as having CFS (p < 0.05) and also thought the patient was significantly more disabled than did individuals in the CBT with graded activity condition (p < 0.05) Jason et al, 2001 (47) Randomized controlled trial, survey of perceptions N = 105 medical trainees (Study 1) N = 141 undergraduate psychology students (Study 2) Randomly assigned to being told the case presented to them had CFS, Florence Nightingale Disease, or ME. The case studies were identical.
Continued on following page
Told case was CFS vs. Florence Nightingale Disease vs. ME Mean score of whether correct diagnosis (1) (2) (3) (4) (5) (6) scale; 1 = not at all and 6 = very likely): 4.5 vs. 3.9 vs. 4.0; p < 0.01 Proportion that associated "causal factors" with diagnosis: 28% vs. 31% vs. 49%; p < 0.01 Mean score of whether diagnosis was associated "organ donor ship" (1-6 scale; 1 = not at all and 6 = very likely): 3.7 vs. 3.5 vs. 3.1; p < 0.05 Lawn et al, 2010 (50) Case series from a specialist CFS clinic. N = 135 patients participating in the PACE trial.
Psychiatric interview using the Structured Clinical Interview for DSM-IV Disorders 102 patients (76%) had a comorbid psychiatric diagnosis; 31% depression, 11% dysthymia, 35% anxiety, 11% social phobia, 15% specific phobia, 6% post-traumatic stress disorder and 2% obsessive compulsive disorder. Newton et al, 2010 (51) Case series from specialist CFS clinic N = 260 patients referred to CFS specialist service between 2008 and 2009.
Reviewed medical notes of patients referred to CFS specialist service Of those referred, 60% were diagnosed with CFS; 40% had alternative diagnosis including other chronic disease (47%), sleep disorder (20%), psychological (15%), idiopathic fatigue (13%), cardiovascular (4%) and other (1%). Reyes et al, 2003 (11) Prospective cohort; random digit-dialing survey and clinical examination with 1-year follow-up telephone interview and clinical examination. N = 3,528 subjects with fatigue 1 month duration (2762 with fatigue 6 months). 3 physicians and 2 psychiatrists independently reviewed each subject's clinical and laboratory data and classified the individual according to the CDC (Fukuda, 1994) criteria.
Descriptive results of exclusionary diagnosis identified in the telephone interview Among 1,155 subjects who had fatigue 6 months, not relieved by rest with 4 of 8 CFS symptoms, 600 had a medical or psychiatric diagnosis. Of 299 subjects without a medical/psychiatric diagnosis who underwent a clinical examination, 43 had CFS, 112 had insufficient symptoms or fatigue, 141 (47.2%) had a medical or psychiatric diagnosis that had not previously been identified and 3 were not classified. Woodward et al, 1995 (52) Qualitative study N = 20 general practitioners (Study 1) and N = 50 patients with diagnosis of CFS (Study 2).
Descriptive results of interviews 14/20 physicians reluctant to diagnosis CFS (scientific uncertainties about condition, beliefs about appropriate professional practice and uncertainty about impact of diagnosis on patient's lives). 45/50 patients stated that diagnosis was the single most helpful event over the course of their illness. Described harms from not having a diagnosis (fear, anxiety, confusion, self-doubt, bitterness). Subjects in this study did not appear to endorse harm from labeling, but helpful CBT = cognitive behavioral therapy; CDC = Centers for Disease Control and Prevention; CFS = chronic fatigue syndrome; DSM-III-R = Diagnostic and Statistical Manual third edition revised; ME = myalgic encephalopathy; PACE = Pacing, grade Activity and Cognitive behavior therapy: a randomized Evaluation.
